Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Novel deoxyguanosine kinase gene mutations and viral infection predispose apparently healthy children to fulminant liver failure.

  • Read more about Novel deoxyguanosine kinase gene mutations and viral infection predispose apparently healthy children to fulminant liver failure.

Presentation of the 2008 Shwachman Award to M. Michael Thaler, MD.

  • Read more about Presentation of the 2008 Shwachman Award to M. Michael Thaler, MD.

Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.

  • Read more about Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.

Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey.

  • Read more about Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey.

Gastritis cystica polyposa.

  • Read more about Gastritis cystica polyposa.

Hepatocarcinoma in viral and metabolic liver disease.

  • Read more about Hepatocarcinoma in viral and metabolic liver disease.

Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics.

  • Read more about Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics.

Extraintestinal manifestations of inflammatory bowel disease.

  • Read more about Extraintestinal manifestations of inflammatory bowel disease.

Body mass index and elbow range of motion in a healthy pediatric population: a possible mechanism of overweight in children.

  • Read more about Body mass index and elbow range of motion in a healthy pediatric population: a possible mechanism of overweight in children.

Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.

  • Read more about Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.

Pagination

  • Previous page ‹‹
  • Page 13
  • Next page ››
Subscribe to Journal of pediatric gastroenterology and nutrition

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List